Form 4: Immunovant Chief Medical Officer Sells Shares to Cover Tax Obligations

Immunovant's Chief Medical Officer, William L. Macias, sold 3,353 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• William L. Macias, Chief Medical Officer of Immunovant, Inc., sold 3,353 shares of common stock on November 20, 2024.
• The sale was executed at a weighted average price of $25.45 per share, with individual transactions ranging from $24.91 to $25.81.
• This transaction was not a discretionary sale but rather a 'sell to cover' transaction mandated by Immunovant to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).
• The RSUs, originally granted on August 17, 2022, had 7,051 units vest on November 17, 2024.
• Following the transaction, Mr. Macias beneficially owns 361,791 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's performance or outlook.

Comparison to Industry Standards

• The 'sell to cover' practice is a standard method for handling tax obligations related to equity compensation in publicly traded companies.
• The transaction is consistent with typical executive stock sales for tax purposes and does not indicate any unusual activity compared to similar companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not affect the company's operations or financial health.

Key Dates

Keywords

Immunovant, IMVT, William L. Macias, Chief Medical Officer, stock sale, restricted stock units, RSUs, tax obligations, sell to cover